language_icon
EN
HI

Jenburkt Pharmaceuticals Share price

JENBURPH

1190

24.05 (2.06%)
Last updated on 13 May, 2026 | 11:05 IST
Today's High

1194.00

Today's Low

1152.15

52 Week Low

944.00

52 Week High

1410.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Jenburkt Pharmaceuticals Chart

Jenburkt Pharmaceuticals Share Key Metrics

Volume
1468.00
Market Cap
514.57 CR
LTQ@LTP
20@1190.00
ATP
1183.6
Var Margin
19.3 %
Circuit Range
932.8-1399.1
Delivery %
62.45 %
Value
17.38 L
ASM/GSM
No
Market Lot
1

Summary

Jenburkt Pharmaceuticals share price stands at ₹1190 at 13 May, 2026 | 11:05. The stock Jenburkt Pharmaceuticals intraday movement has stayed between ₹1152.15 and ₹1194.00, while on a 52-week basis it has fluctuated from ₹944.00 to ₹1410.00.
In terms of trading activity, Jenburkt Pharmaceuticals has recorded a volume of 1468 shares. The Jenburkt Pharmaceuticals has a market cap of ₹4413300. The stock’s Average Traded Price (ATP) stands at ₹118360, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 20, 119000.
The Jenburkt Pharmaceuticals operates within a circuit range of ₹932.8-1399.1 – ₹932.8-1399.1, with a Value of ₹17.38 L. The Delivery Percentage for the day is 62.45%. Additionally, Jenburkt Pharmaceuticals currently falls under the No framework, and trades with a market lot size of 1.

Jenburkt Pharmaceuticals Fundamentals

View More
P/E Ratio

0

P/B Ratio

0

Div. Yield

0

Sector P/E

68.8

Sector P/B

3.58

Sec. Div. Yield

0.56

Jenburkt Pharmaceuticals Resistance and Support

Pivot 1161.08

Resistance

First Resistance

1189.56

Second Resistance

1213.18

Third Resistance

1241.66

Support

First Support

1137.46

Second Support

1108.98

Third Support

1085.36

Jenburkt Pharmaceuticals Shareholding Pattern

View More
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
  • 2020-21
  • 2019-20
  • 2018-19
  • 2016-17
Total Promoters
Segment
Percent

Total Promoters

45.81%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0%

Domestic Institutional Investors

0%

Retail

54.19%

Others

0%

Total Promoters
MAR '16
45.96%
SEP '16
45.81%

Jenburkt Pharmaceuticals Corporate Actions

DateAgenda
2026-05-05Audited Results
2026-02-03Quarterly Results
2025-10-28Quarterly Results
2025-08-12Quarterly Results
2025-05-20Audited Results & Final Dividend
2025-01-28Quarterly Results

Jenburkt Pharmaceuticals News

Jenburkt Pharmaceuticals Ltd - 524731 - Intimation Of Record Date And Cut-Off Date

Jenburkt Pharmaceuticals fixed August 28, 2026, as record date for dividend payment for FY26. This date also determines e-voting eligibility for the 41st Annual General Meeting scheduled on September 04, 2026.
May 06 2026 14:05:00

Jenburkt Pharmaceuticals Ltd - 524731 - Announcement under Regulation 30 (LODR)-Change in Management

Jenburkt Pharmaceuticals re-appointed Shri Dilip H. Bhuta as Whole Time Director and CFO for a five-year term, effective April 1, 2027 to March 31, 2032. This re-appointment provides leadership stability and continuity.
May 05 2026 19:05:00

Jenburkt Pharmaceuticals Ltd - 524731 - Board Meeting Outcome for Outcome Of Board Meeting Held On 05Th May, 2026.

Jenburkt Pharmaceuticals board approved the audited financial results for FY26, reporting ₹168.74 crore in revenue and ₹34.74 crore in net profit. The board also declared a final dividend of ₹20.70 per equity share and re-appointed Shri Dilip H. Bhuta as Whole Time Director and CFO for five years.
May 05 2026 19:05:00

Jenburkt Pharmaceuticals Ltd - 524731 - Board Meeting Intimation for Taking On Record The Audited Financial Results For The Quarter And Financial Year Ended On 31St March, 2026 And To Consider Recommendation Of Dividend, If Any.

Jenburkt Pharmaceuticals' Board of Directors will convene on May 05, 2026. The agenda includes approval of audited financial results for Q4 FY26 and the full financial year, along with considering a dividend recommendation.
Apr 28 2026 16:04:00
Read More

About Jenburkt Pharmaceuticals

NSE : 0  
BSE : 524731  
ISIN : INE354A01013  

The Company was originally incorporated as a PrivateLimited Company on 10th June 1985 in the state ofMaharastra Bombay and subsequently converted into a PublicLimited Company on 4th January 1994 and obtainedcertificate of change of name from the Registrar ofCompanies on 31 st January 1994. The Company has been promoted by ''BHUTA'' Family. The Bhutafamily is having interest in various business activitiessuch as manufacturing and marketing of pharmaceuticalformulations trading in Chemicals Textiles etc. Thegroup turnover in the year 1992-93 was Rs. 1616.85 lacs andover Rs. 2000 Lacs (provisional) for the year 1993-94.Now the Company has taken over the existing business of agroup partnership firm i.e. M/s Jenburkt Pharmaceuticalsa going concern which was engaged in the manufacturing andmarketing of pharmaceuticals formulation on Loan Licencebasis under various brand name registered with appropriateauthorities in the name of firm. Brief history of the said partnership firm is as under: M/S Jenburkt Pharmaceuticals was established in the year1984-85 by Mr. Harshad Bhuta along with his brothers.Initially the firm started manufacturing and marketing ofpharmaceuticals formulations under loan and licence basis.Mainly the products under different therapeutic groupnamely nutritional supplement cough syrup-expectorantHaematinic syrup. Initially the firm had launched theirproducts only in Bombay and some parts of MaharashtraGujarat and Madhya Pradesh. Over last Ten years the firmhad successfully launched more than 15 products and it hasexpanded its marketing 10 times to include areas likemetropolitan Delhi Key areas of Uttar Pradesh RajasthanHaryana Karnataka Goa Andhra Pradesh and Kerala. Its field force had consistently grown from 25 to 170people.Jenburkt Products were made available through a wide spreadnetwork of stockists and super stockists through whom theproducts were distributed to thousands of retail chemistoutlets. The firm had a consistent track record of growthand its turnover had increased to Rs. 484 Lacs during 1993-94 from Rs. 39.92 Lacs in the year 1985-86.MAIN OBJECTS OF THE COMPANYTHE MAIN OBJECTS OF THE COMPANY AS PER MEMORANDUM OFASSOCIATION ARE:- 1. To carry on all or any of the business of manufacturersimporters exporters buyers sellers and distributingagents of and dealers in all kinds of patentpharmaceuticals medicinal and medicated preparationspatent medicines drugs herbs and in pharmaceuticalmedicinal proprietary and industrial preparationscompounds and articles of all kinds and chemicalmanufacturers.SUBSIDIARY COMPANYThe company has no subsidiary.

Read More

Jenburkt Pharmaceuticals Management

NamePosition
Ashish U BhutaChairman & Managing Director
Dilip H BhutaWhole Time Director & Chief Financial Officer
View More

Jenburkt Pharmaceuticals FAQs

The Buying Price of Jenburkt Pharmaceuticals share is 1190 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Jenburkt Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Jenburkt Pharmaceuticals, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Jenburkt Pharmaceuticals shares is 0. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Jenburkt Pharmaceuticals shares is 0. Useful to assess the stock's value relative to its book value.

To assess Jenburkt Pharmaceuticals’s valuation compare Sector P/E, P/B which are 68.8 & 3.58 with sector averages, along with growth rates and financial metrics.

The Market Cap of Jenburkt Pharmaceuticals is 514.57 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Jenburkt Pharmaceuticals share price is 1410.00 & 944.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Jenburkt Pharmaceuticals belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost